describ
five
case
children
complet
chemotherapi
infantil
acut
lymphoblast
leukemia
soon
diagnos
sever
tcell
nonhiv
immunodefici
vari
bcell
nkcell
deplet
near
absenc
cell
patient
develop
multipl
primarili
opportunist
infect
unfortun
four
patient
die
although
one
success
treat
hematopoiet
stem
cell
transplant
immunodefici
appear
secondari
intens
infant
chemotherapi
report
highlight
import
earli
consider
lifethreaten
immun
complic
patient
receiv
chemotherapi
infantil
death
immunocompromis
host
immunodefici
infant
leukemia
molecular
diagnosi
therapi
intensif
therapi
infant
acut
lymphoblast
leukemia
result
fewer
relaps
cost
increas
morbid
death
especi
induct
therapi
increas
nonhematolog
toxic
modern
treatment
strategi
infant
report
sever
immunodefici
persist
therapi
describ
immunodefici
classifi
acquir
primari
pid
congenit
tcell
immunodefici
defin
less
cell
l
gener
sever
compar
immunodefici
sinc
tcell
also
play
crucial
role
function
bcell
nkcell
macrophag
chemotherapi
known
induc
immunodefici
state
significantli
deplet
tcell
well
nkcell
bcell
usual
immun
reconstitut
begin
complet
chemotherapi
children
greater
year
age
receiv
intens
chemotherapi
treatment
highrisk
tcell
recoveri
complet
month
cessat
chemotherapi
addit
absolut
count
month
greater
cell
l
patient
describ
five
children
complet
treatment
infantil
soon
diagnos
persist
sever
tcell
nonhiv
immunodefici
vari
bcell
nkcell
deplet
result
sever
infect
caus
death
four
success
hematopoiet
stem
cell
transplant
hsct
one
immun
defici
appear
secondari
therapi
report
highlight
import
consid
complic
patient
infant
post
chemotherapi
iwk
health
centr
research
ethic
board
review
manuscript
provid
letter
support
collect
data
five
infant
case
four
femal
one
male
treat
three
center
north
america
clinic
treatment
characterist
shown
tabl
describ
first
report
nonhiv
persist
tcell
immunodefici
vari
bcell
nkcell
deplet
patient
infant
follow
modern
intens
chemotherapi
patient
cohort
remain
mildli
sever
lymphopen
flow
cytometri
demonstr
extrem
low
tcell
popul
consist
sever
tcell
immunodefici
despit
complet
chemotherapi
treatment
month
prior
believ
unlik
patient
unrecogn
pid
none
patient
strong
identifi
pid
failur
thrive
intraven
antimicrobi
use
prior
diagnosi
patient
b
distant
famili
histori
defici
carri
mutat
investig
prior
start
chemotherapi
suggest
patient
b
c
expos
viral
infect
major
complic
final
patient
e
extens
genet
workup
exclud
common
scid
mutat
patient
c
normal
trec
assay
base
describ
histori
investig
conclud
secondari
immunodefici
produc
chemotherapi
studi
immun
reconstitut
children
receiv
chemotherapi
hematolog
malign
demonstr
children
total
lymphocyt
count
recov
within
month
total
bcell
count
normal
children
month
children
month
chemotherapi
cessat
nkcell
ta
b
l
e
immunolog
investig
assess
immun
function
caus
immun
defici
initi
thought
total
recov
within
month
cessat
recent
studi
shown
delay
drop
may
take
month
fulli
recov
tcell
recoveri
subset
shown
direct
relationship
intens
therapi
invers
relationship
age
invers
relationship
thought
tcell
recov
rapidli
thymicdepend
pathway
normal
thymic
involut
begin
approxim
year
age
thymic
enlarg
post
chemotherapi
demonstr
pediatr
patient
children
treat
standardrisk
highrisk
tcell
requir
month
recov
count
month
greater
cell
l
regardless
treatment
intens
despit
prolong
impair
immun
function
sever
opportunist
infect
typic
appreci
cessat
chemotherapi
death
infect
rare
tcell
recoveri
pattern
seen
patient
addit
cyclophosphamid
cytarabin
associ
deplet
earli
lineag
tcell
thu
affect
tcell
prolifer
although
patient
treat
prior
cyclophosphamid
elimin
induct
patient
expos
cumul
cyclophosphamid
dose
least
doubl
standardrisk
highrisk
protocol
use
older
children
possibl
higher
dose
cyclophosphamid
thank
patient
famili
describ
seri
author
declar
conflict
interest
hsct
hematopoiet
stem
cell
transplant
pid
primari
immunodefici
scid
sever
combin
immunodefici
trec
tcell
receptor
excis
circl
